Navari - Pre-clinical study of software based AR-tool for safer cancer removal.
| Reference number | |
| Coordinator | Navari Surgical AB |
| Funding from Vinnova | SEK 324 500 |
| Project duration | November 2022 - December 2023 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Impact Startups autumn 2022 |
Important results from the project
In this call, Navari applied for funding with the aim of being able to test its technology in its proper environment for the first time, in a pre-clinical study. The goal was for the product to be tested by end users in its intended environment, in order to generate significant data and thus get closer to a clinical study. After completing the project, it can be stated that Navari has conducted a successful study where a Proof of Concept in vivo has been achieved. The technology worked as intended and a large amount of valuable feedback and data has been compiled.
Expected long term effects
The project has led to Navari´s technology being tested for the first time in its intended environment, where a large amount of necessary data and feedback has been generated. This can now be used in the further development of Navari´s technology. With the completion of the study and a positive outcome in said study, a major risk element in the development of a medical device product is completed. Navari has taken a big step closer to the market where the next major upcoming milestone is a clinical study.
Approach and implementation
The project was carried out continuously during 2023, where a large part of the work involved planning, coordinating and compiling the necessary material, equipment and documentation required to carry out the study. The study itself was conducted during weeks 37-38 at Experimental Biomedicine in Gothenburg, where Navari´s technology could be validated for the first time in the intended environment. The data has since been analysed and compiled and will now be implemented in future product development.